TANGO THERAPEUTICS INC (TNGX)
US87583X1090 - Common Stock
TNGX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. While TNGX has a great health rating, there are worries on its profitability. TNGX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year TNGX has reported negative net income.
In the past year TNGX has reported a negative cash flow from operations.
TNGX had negative earnings in each of the past 5 years.
In the past 5 years TNGX always reported negative operating cash flow.
1.2 Ratios
TNGX has a Return On Assets of -35.01%. This is in the better half of the industry: TNGX outperforms 62.39% of its industry peers.
TNGX has a better Return On Equity (-53.84%) than 65.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.01% | ||
| ROE | -53.84% | ||
| ROIC | N/A |
ROA(3y)-20.57%
ROA(5y)N/A
ROE(3y)-33.48%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for TNGX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TNGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TNGX has been increased compared to 1 year ago.
There is no outstanding debt for TNGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
TNGX has an Altman-Z score of 0.00. This is a bad value and indicates that TNGX is not financially healthy and even has some risk of bankruptcy.
TNGX has a Altman-Z score of 0.00. This is in the better half of the industry: TNGX outperforms 64.88% of its industry peers.
There is no outstanding debt for TNGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0 |
ROIC/WACCN/A
WACC10.4%
2.3 Liquidity
A Current Ratio of 8.00 indicates that TNGX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 8.00, TNGX is in the better half of the industry, outperforming 73.80% of the companies in the same industry.
A Quick Ratio of 8.00 indicates that TNGX has no problem at all paying its short term obligations.
TNGX has a better Quick ratio (8.00) than 74.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8 | ||
| Quick Ratio | 8 |
3. Growth
3.1 Past
The earnings per share for TNGX have decreased by -6.31% in the last year.
The Revenue has grown by 15.66% in the past year. This is quite good.
EPS 1Y (TTM)-6.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.39%
Revenue 1Y (TTM)15.66%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%8.15%
3.2 Future
TNGX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -10.08% yearly.
Based on estimates for the next years, TNGX will show a very strong growth in Revenue. The Revenue will grow by 21.34% on average per year.
EPS Next Y-14.03%
EPS Next 2Y-15.97%
EPS Next 3Y-10.44%
EPS Next 5Y-10.08%
Revenue Next Year16.4%
Revenue Next 2Y-14.25%
Revenue Next 3Y-8.04%
Revenue Next 5Y21.34%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TNGX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TNGX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as TNGX's earnings are expected to decrease with -10.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.97%
EPS Next 3Y-10.44%
5. Dividend
5.1 Amount
TNGX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TANGO THERAPEUTICS INC
NASDAQ:TNGX (11/20/2024, 8:00:00 PM)
Premarket: 4.07 -0.01 (-0.25%)4.08
+0.23 (+5.97%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap438.27M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.01% | ||
| ROE | -53.84% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 8 | ||
| Quick Ratio | 8 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-6.31%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-14.03%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)15.66%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y